Table II.
Univariate analysis of clinical characteristics affecting OS time.
| Clinical characteristics | Number (n=25) | OS (95% CI) | P-value |
|---|---|---|---|
| Sex | 0.373 | ||
| Male | 22 | 14.97 (7.75–22.19) | |
| Female | 3 | 9.87 | |
| ECOG performance status | 0.174 | ||
| 0/1 | 22 | 18.62 (10.86–26.38) | |
| 2 | 3 | 9.87 (9.18–10.56) | |
| Tumor location | 0.482 | ||
| Upper 1/3 | 13 | 14.97 (3.73–26.21) | |
| Middle 1/3 | 10 | 13.52 (1.34–25.70) | |
| Lower 1/3 | 2 | 9.44 | |
| Differentiation | 0.221 | ||
| Well | |||
| Moderate | 15 | 11.91 (5.22–18.60) | |
| Poor | 8 | 21.11 (6.01–35.17) | |
| Unknown | 1 | ||
| N stage | 0.131 | ||
| Positive | 18 | 12.93 (7.63–18.22) | |
| Negative | 7 | 23.07 (7.96–36.20) | |
| Tumor biomarkers | 0.258 | ||
| Normal | 14 | 11.91 (3.91–19.91) | |
| Abnormal | 11 | 18.62 (8.50–28.74) | |
| Chemotherapy before radiation | 0.350 | ||
| Yes | 14 | 14.97 (6.27–23.67) | |
| No | 11 | 13.95 (0.94–26.96) | |
| Chemoradiotherapy | 0.552 | ||
| Yes | 10 | 18.62 (10.80–26.44) | |
| No | 15 | 13.52 (4.82–22.22) | |
| ctDNA status in first post-treatment plasma | 0.005 | ||
| Negative | 10 | 33.68 (15.66–51.70) | |
| Positive | 14 | 11.91 (5.22–18.60) |
OS, overall survival; ECOG, Eastern Cooperative Oncology Group; ct, circulating tumor.